Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 3/20 | 0.45 |
| ▸ | AKT2 | P31751 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060970 | 0.84 | CYP2D6 (0.59) | MAPTCYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13527239 | 0.81 | CYP2D6 (0.56) | RARBMAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL29941524 | 0.80 | AKT2 (0.64) | AKT1AKT2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL13526916 | 0.79 | AKT2 (0.44) | AKT1AKT2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL21157729 | 0.78 | RARB (0.52) | RARBTDP1MAPTKMT2ACYP2D6 | |
| SCHEMBL13251245 | 0.77 | RARB (0.62) | RARBTDP1MAPT | |
| SCHEMBL21156450 | 0.77 | RARB (0.51) | RARBTDP1MAPTKMT2ACYP2D6 | |
| SCHEMBL14466665 | 0.76 | AKT2 (0.59) | AKT1AKT2ROCK2 | |
| SCHEMBL21157749 | 0.76 | RARB (0.60) | RARBTDP1CYP2D6CYP3A4 | |
| SCHEMBL7334158 | 0.76 | RARB (0.56) | RARBTDP1MAPTKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | RARB 3457/4885AKT1 2994/4885AKT2 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.